Loading...
Loading...
SLP| Name | Value |
|---|---|
| Revenues | 12.0M |
| Cost of Revenue | 2.7M |
| Gross Profit | 9.3M |
| Operating Expense | 8.4M |
| Operating I/L | -0.0M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.8M |
| Pretax | 1.6M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | 1.2M |
Simulations Plus, Inc. develops drug discovery and development software utilizing artificial intelligence and machine learning technology. It offers simulation products such as GastroPlus, DDDPlus, and MembranePlus, as well as mechanistic and mathematical models like DILIsym, NAFLDsym, and MITOsym. The company also provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor, MedChem Designer, MonolixSuite, and PKPlus. Additionally, it offers contract research services, training, and consulting services for pharmacometrics studies, and clinical-pharmacology-based consulting services. Its clients include pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies.
